Develops immune-modulation therapeutics targeting TNFR2 for autoimmune diseases
| Date | Round | Amount |
|---|---|---|
| May 2023 | Series A Belgian biotech Dualyx raised a 40m EUR Series A co-led by Fountain Healthcare Partners, Forbion and Andera Partners to advance its DT-001 autoimmune programme. | $43M |